[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 346
Citations 0
Research Letter
July 2016

Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell LymphomaA Phase 2 Clinical Trial

Author Affiliations
  • 1Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
  • 2Private Practice, Feldmeilen, Switzerland
  • 3Department of Dermatology, Medical University of Graz, Graz, Austria
  • 4Department of Dermatology, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany
  • 5Department of Dermatology, Nantes University Hospital, Nantes, France
  • 6Henri Mondor Hospital, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
JAMA Dermatol. 2016;152(7):837-839. doi:10.1001/jamadermatol.2016.0401

For cutaneous T-cell lymphoma (CTCL),1 there is need for new treatment options. APO866 is an injectable molecule that induces cell death by inhibiting the biosynthesis of NAD+ (oxidized nicotinamide adenine dinucleotide), which is essential for cell survival.24 Previous studies have shown in vitro and in vivo that lymphocytes and hematologic cancer cells are very sensitive to APO866, which induced cell death at low concentration in various human tumor cells, including lymphomas.5

First Page Preview View Large
First page PDF preview
First page PDF preview
×